NCT06562790View on ClinicalTrials.gov

Study of Gamma PN3 in the Elderly

PHASE1CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

August 26, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Pneumonia, Pneumococcal
Interventions
BIOLOGICAL

Gamma PN3

500, 1000 or 1500 µg by IM injection on Days 1 and 29

BIOLOGICAL

Prevnar

1 dose on Day 1 and saline placebo on Day 29

Trial Locations (1)

5065

CMAX Fusion, Adelaide

Sponsors

Lead Sponsor

GPN Vaccines
All Listed Sponsors
lead

GPN Vaccines

INDUSTRY

NCT06562790 - Study of Gamma PN3 in the Elderly | Biotech Hunter | Biotech Hunter